【摘要】 目的探讨肺腺癌组织程序性细胞死亡蛋白-1(PD-1)及其配体(PD-L1)表达水平对晚期肺腺癌放化疗后预后判断的价值。方法回顾性分析2016年1月至2017年12月广西钦州市第二人民医院初治确诊的肺腺癌患者114例的病例资料。对比分析肺腺癌组织PD-1及PD-L1表达阳性与晚期肺腺癌放化疗3个月预后的相关性。结果晚期肺腺癌组织PD-1或者PD-L1表达阳性的患者在放化疗3个月后预后效果均显著低于PD-1或者PDL1表达阴性的患者,差异均具有统计学意义(P <0. 05)。结论阻断PD-1与PD-L1结合的治疗方案对于晚期肺腺癌组织PD-1或者PD-L1表达阳性的患者可能获得更好的临床获益,需引起临床上引起重视。更多还原

【Abstract】 Objective To investigate the prognostic value of PD-1 and PD-L1 expression in patients with advanced lung adenocarcinoma after chemoradiotherapy. Methods The data of 114 cases of lung adenocarcinoma diagnosed in our hospital from January 2016 to December2017 were analyzed retrospectively. The correlation between the positive expression of PD-1 and PD-L1 in lung adenocarcinoma tissue and the prognosis of advanced lung adenocarcinoma for 3 months was analyzed. Results After 3 months of chemotherapy,the prognosis of patients with advanced lung adenocarcinoma with positive PD-1 or PD-L1 expression was significantly lower than that of PD-1 or PD-L1 negative( P <0. 05). Conclusion The combination of PD-1 and PD-L1 therapy for patients with PD-1 or PD-L1 expression in advanced lung adenocarcinoma tissue may gain better clinical benefits than chemotherapy,which should cause clinical attention.更多还原